Recording and Reporting of Antimicrobial Resistance (AMR) Priority Variables and Its Implication on Expanding Surveillance Sites in Nepal: A CAPTURA Experience.

Autor:	Maharjan S; Public Health Research, Anweshan Private Limited, Lalitpur, Nepal., Gallagher P; Public Health Surveillance Group, LLC, Princeton, New Jersey, USA., Gautam M; Public Health Research, Anweshan Private Limited, Lalitpur, Nepal., Joh HS; International Vaccine Institute, Seoul, Republic of Korea., Sujan MJ; International Vaccine Institute, Seoul, Republic of Korea., Aboushady AT; International Vaccine Institute, Seoul, Republic of Korea.; Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Kwon SY; International Vaccine Institute, Seoul, Republic of Korea., Gautam S; International Vaccine Institute, Seoul, Republic of Korea.; Research & Collaboration, Anka Analytica, Melbourne, Australia., Upadhyaya MK; Ministry of Health and Population, Government of Nepal, Kathmandu, Nepal., Jha R; National Public Health Laboratory, Department of Health Services, Ministry of Health and Population, Kathmandu, Nepal., Acharya J; National Public Health Laboratory, Department of Health Services, Ministry of Health and Population, Kathmandu, Nepal., MacWright WR; Public Health Surveillance Group, LLC, Princeton, New Jersey, USA., Marks F; International Vaccine Institute, Seoul, Republic of Korea.; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.; Madagascar Institute for Vaccine Research, University of Antananarivo, Madagascar., Stelling J; Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Poudyal N; International Vaccine Institute, Seoul, Republic of Korea.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Dec 20; Vol. 77 (Suppl 7), pp. S560-S568.
DOI:	10.1093/cid/ciad581
Abstrakt:	Data on antimicrobial resistance (AMR) from sites not participating in the National AMR surveillance network, conducted by National Public Health Laboratory (NPHL), remain largely unknown in Nepal. The "Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia" (CAPTURA) assessed AMR data from previously untapped data sources in Nepal. A retrospective cross-sectional data review was carried out for the AMR data recorded between January 2017 and December 2019 to analyze AMR data from 26 hospital-based laboratories and 2 diagnostic laboratories in Nepal. Of the 56 health facilities initially contacted to participate in this project activity, 50.0% (28/56) signed a data-sharing agreement with CAPTURA. Eleven of the 28 hospitals were AMR surveillance sites, whereas the other 17, although not part of the National AMR surveillance network, recorded AMR-related data. Data for 663 602 isolates obtained from 580 038 patients were analyzed. A complete record of the 11 CAPTURA priority variables was obtained from 45.5% (5/11) of government hospitals, 63.6% (7/11) of private hospitals, and 54.6% (6/11) of public-private hospitals networked with NPHL for AMR surveillance. Similarly, 80% (8/10) of clinics and 54.6% (6/11) of laboratories outside the NPHL network recorded complete data for the 10 Global Antimicrobial Resistance and Use Surveillance System (GLASS) priority variables and 11/14 CAPTURA priority variables. Retrospective review of the data identified areas requiring additional resources and interventions to improve the quality of data on AMR in Nepal. Furthermore, we observed no difference in the priority variables reported by sites within or outside the NPHL network, thus suggesting that policies could be made to expand the surveillance system to include these sites without substantially affecting the government's budget. Competing Interests: Potential conflicts of interest. S. M. reports payments made to their institution from the International Vaccine Institute; grants and contracts from the International Vaccine Institute; payment made to their institution from Anweshan Private Limited; support for attending meetings as part of the project implementation plan, multiple meetings with stakeholders and hospital authority were required that needed distant travelling. P. G. reports receiving compensation from the International Vaccine Institute. M. G. reports payments made to their institution from the International Vaccine Institute; payments made to their institution from Anweshan Private limited; and received travel support as part of the project implementation plan, multiple meetings with stakeholders and hospital authority were required that needed distant travelling. M. J. S. reports working as a CAPTURA Country Coordinator for Bangladesh from 2020 to 2022; worked as a full-time staff member of the International Vaccine Institute in Seoul and supported the CAPTURA implementation; received consultancy fees from the International Vaccine Institute. A. T. A. reports working as an employee of Brigham and Women's Hospital since April 2021; received consultancy fees for work with CAPTURA project as a consultant between September 2021 and March 2022. S. G. reports receiving consultancy payments for manuscript preparation; and salary support from the International Vaccine Institute. J. S. reports salary support through a subcontract. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu